Issued Patents derived from our laboratory research:
1. U.S. patent,5,578,716 DNA methyltransferase antisense oligonucleotides
2. U. S. patent 5,5919,772 Antisense oligonucleotides having tumoreginicity inhibiting activity.
3. U. S. patent 6,054,439 antisense oligonucleotides having tumoreginicity inhibiting activity.
4. U. S. patent 6,184,211 Inhibition of DNA methyltransferase
5. 5. U. S. patent 6,066,625 Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences.
6. Published PCT application: DNA demethylase therapeutic and diagnostic uses thereof PCT 1770-183.
Current Projects in the laboratory:
Delineating
the mechanisms responsible for cell cycle regulation of DNMT1 3'UTR elements and
proteins interacting with them
-involvement of cell cycle regulation of DNMT1 in tumorigenesis
-Unraveling the mechanisms through which DNMT1 inhibitors block tumorigenesis
-methylation independent mechanisms of regulation of
gene expression by DNMT1 inhibitors
-understanding the mechanisms through which DNMT1 regulates DNA replication
Deciphering
mechanisms of active demethylation
-understanding the links between chromatin structure and demethylase
-structure function analysis of MBD2/demethylase
-mechanism of the demethylase reaction
Analyzing the role of demethylase, MBD2 and global demethylation in tumorigenesis and behavioral imprinting